Breast cancer Cancer Breast
Conditions
Interventions
Patients are randomised to one of four treatment groups:
1. Group A: Loading dose medroxyprogesterone acetate (MPA), 1 g every 6 h for eight doses, followed by low dose maintenance 500 mg MPA daily
Sponsors
UK Co-ordinating Committee for Cancer Research (UKCCCR)
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Histologically proven advanced or metastatic disease 2. Measurable or assessable disease 3. Previously treated with tamoxifen resulting in relapse or no response 4. No previous therapy with medroxyprogesterone acetate (MPA) or other progesterones 5. No anti-cancer therapy within the preceding 4 weeks, but patients who, having stopped prior therapy show evidence of disease progression during the 4th week interval between treatments may enter the trial forthwith 6. Able to tolerate 8 weeks hormonal therapy 7. No evidence of brain metastases 8. No pre-existing malignancy, except non-melanomatous skin cancer
Exclusion criteria
Exclusion criteria: Not provided at time of registration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed